Ryan Thaliffdeen (0009-0000-7231-1471) - ORCID

We notice you are using a browser that our site does not support. Some features on this site may not work correctly. We recommend that you upgrade to a supported browser.

Personal information

No personal information available

Activities

Collapse all

Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model

Clinical Drug Investigation

2024-03 | Journal article

DOI: 10.1007/s40261-024-01345-3

Contributors: Ryan Thaliffdeen; Anthony Yu; Karen Rascati

Show more detail

Source:

check_circle

Crossref

How many people are using ORCID?